Literature DB >> 31076046

Evolution of the Intensive Care Unit Telemedicine Value Proposition.

Craig M Lilly1, Jared T Mickelson2.   

Abstract

Advances in clinical information sciences, telecommunication technologies, electronic health records, early warning systems, automated acuity assessment, and clinician communication support systems have allowed current-generation intensive care (ICU) telemedicine systems to address the inefficiencies of the failed advice-upon-request ICU telemedicine model. Value is related to the ability of health care systems to leverage ICU telemedicine resources to provide care. Local financial benefits of ICU telemedicine program implementation depend on changing behavior to better focus on activities that reduce the duration of critical illness and length of stay.
Copyright © 2019 Elsevier Inc. All rights reserved.

Keywords:  Case volume; Costs; Direct contribution margin; Financial performance; Outcomes; Processes of care; Revenue; Telemedicine intensive are unit

Mesh:

Year:  2019        PMID: 31076046     DOI: 10.1016/j.ccc.2019.02.010

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  3 in total

1.  Communication and role clarity inform TeleICU use: a qualitative analysis of opportunities and barriers in an established program using AACN framework.

Authors:  Anna Krupp; Michael Di Martino; Wesley Chung; Krisda Chaiyachati; Anish K Agarwal; Ann Marie Huffenberger; Krzysztof Laudanski
Journal:  BMC Health Serv Res       Date:  2021-03-25       Impact factor: 2.655

2.  Electronic intensive care unit: A perspective amid the COVID-19 era - Need of the day!

Authors:  Karthikeyan P Iyengar; Rakesh Garg; Vijay Kumar Jain; Nipun Malhotra; Pranav Ish
Journal:  Lung India       Date:  2021-03

Review 3.  Telemedicine in Intensive Care Units: Scoping Review.

Authors:  Camille Guinemer; Martin Boeker; Daniel Fürstenau; Akira-Sebastian Poncette; Björn Weiss; Rudolf Mörgeli; Felix Balzer
Journal:  J Med Internet Res       Date:  2021-11-03       Impact factor: 5.428

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.